Wolverine Stack
BPC-157 + TB-500 injury-recovery peptide pairing
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The combination as a combination is essentially unstudied. There is no published human trial, no controlled animal experiment, and no pharmacokinetic work testing BPC-157 alongside TB-500, so any claim that the two are synergistic is inference from separate literatures rather than a finding. What exists sits at the component level and mostly in rodents. BPC-157 has a large animal literature, much of it produced by the Zagreb group that discovered it, reporting accelerated healing of tendon, ligament, muscle, and gut tissue in rats. That body of work is unusually concentrated in one research lineage and has seen little independent replication, and the small number of human exposures come from early gastrointestinal trials of the related compound PL 14736 rather than from injury recovery. Thymosin beta-4 has stronger biological plausibility as a repair protein and reached human trials for corneal and dermal wounds, but those trials used full-length Tβ4 rather than the fragment vendors sell as TB-500, and results did not carry it to approval. Reports of benefit in the stack are anecdotal, uncontrolled, and confounded by rest and rehabilitation.
Counted on the record: 0 human studies, 0 randomized trials, 0 participants, 0 animal studies, 0 lab studies.
- FDA
- Not FDA-approved for any use. Neither peptide is an approved drug. The FDA placed BPC-157 in Category 2 of the 503A compounding bulk-substances list in 2023-2024, citing safety concerns and lack of human data; an April 2026 HHS announcement signaled intent to remove it from Category 2, but that process was not finalized at the time of writing.
- WADA
- Prohibited
Reference only. Not medical advice.
What can go wrong
High uncertainty. Not FDA-approved; both peptides are sold mostly as 'research chemicals' not intended for human use, so purity, dose accuracy, and sterility are unregulated and vary by seller. Human safety and effectiveness data are very limited, and long-term effects are unknown. Theoretical concerns include unwanted blood-vessel growth (angiogenesis) and tumor promotion, though these are not established in humans. Banned in competitive sport. The FDA restricted BPC-157 from compounding pharmacies in 2023-2024.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Wolverine Stack. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
The Wolverine Stack is an informal nickname for combining two injectable peptides, BPC-157 (Body Protection Compound 157) and TB-500 (a synthetic peptide related to a fragment of Thymosin Beta-4). People use the pairing in hopes of speeding recovery from tendon, ligament, and muscle injuries.The 'Wolverine' name is a pop-culture reference to the Marvel character's rapid healing and was not coined by any identified researcher or clinic. It is a community label, not a tested medical regimen.
injury recovery
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The pathway is not proposed and only hypothesized.
- Step 1Tissue Injury/RepairLocal tissue damage creates hypoxia, disrupted extracellular matrix, inflammatory signaling, and a need for endothelial cells and fibroblasts/tenocytes to migrate into the damaged region.
- Step 2Endothelial RepairBPC-157's FAK/paxillin + VEGFR2/eNOS arms and the proposed TB-500 actin/motility arm theoretically converge on greater endothelial-cell movement, fibroblast/tenocyte migration, and organization of the damaged tissue environment.
- Step 3Tissue Repair/RemodelingTheoretical endpoint: improved perfusion + cell survival + cell migration + matrix reconstruction → more organized wound/tendon/soft-tissue repair.
- Step 4Angiogenesis/ECM remodelingncreased endothelial sprouting plus migration of repair cells may support formation of new microvasculature, matrix turnover, and subsequent collagen deposition/remodeling. These individual outcomes have been demonstrated primarily in preclinical BPC-157, thymosin-β4, and LKKTETQ models
This is hypothesized based on the studied mechanism of action of TB-500 and BPC-157. Only tested in a lab and in animals.
Combined
None reported
Two animal-model pathways, never tested together
The Wolverine Stack is a street name for pairing BPC-157 with TB-500. The idea behind it is that two healing signals added together will speed repair of tendons, ligaments and muscle. Looked at closely, each half rests on a different kind of evidence, and neither holds up well as a human mechanism. The argument for the combination depends on the two pathways adding together or working in synergy. In theory, BPC-157 builds the "roads and supply lines" (blood vessels), while TB-500 actively moves the "construction workers" (repair cells) down those lines to the site of an injury
Safety in detail
- No clinical trial has tested BPC-157 and TB-500 together in people. Nobody has measured whether the two interact, so any safety picture for the combination has yet to be recorded.
- BPC-157 human safety data are very sparse. An IRB-approved pilot study gave intravenous BPC-157 to 2 healthy adults and reported no adverse effects. With only two participants, it cannot rule out uncommon or long-term harms.
- Both components are marketed mostly as research chemicals. The FDA has warned that unapproved injectable peptide products carry contamination and dosing risks, so the identity, purity and sterility of any given vial are uncertain.
What people get wrong
Often saidMyth: It is proven to heal injuries 'like Wolverine.'
ActuallyReality: The name is a comic-book reference; controlled human evidence for accelerated healing is essentially absent (American Journal of Sports Medicine systematic review, 2025).
Often saidMyth: If a clinic sells it, it must be FDA-approved.
ActuallyReality: It is not approved; the FDA placed BPC-157 in compounding Category 2 in 2023-2024 over safety and data concerns.
Often saidMyth: 'Research chemical' grade is the same as pharmaceutical grade.
ActuallyReality: Research-chemical vendors are not held to drug-manufacturing standards, so purity and dosing are unverified (OPSS/Department of Defense advisory).
Who profits, and who pushes back
US Anti-Doping Agency (USADA)
BPC-157 is an experimental peptide that creates real risk for athletes and is prohibited at all times (2023).
American Journal of Sports Medicine systematic review
Of 544 articles screened, only one human clinical study met inclusion criteria; the rest were preclinical (2025).
Operation Supplement Safety (OPSS, US Department of Defense)
BPC-157 is a prohibited peptide and an unapproved drug found in wellness products (advisory).
Telehealth and concierge peptide clinics (e.g. Drip Hydration, ConciergeMD)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Marketing pages promote the 'Wolverine Stack' by name; they profit from sale.
Online research-chemical vendors
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Sell labeled 'not for human consumption' while customers self-inject.
Bodybuilding and biohacker forums
Believer-driven anecdote; the 'Wolverine' nickname spread here.
Fitness and longevity podcasters/influencers
Mix of genuine enthusiasm and occasional affiliate ties; varies by individual.
Where the research comes from
Most of the published research on this comes from one place. 55% of it is from North America. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| North America | 55% |
| Europe | 20% |
| Asia-Pacific | 15% |
| Latin America | 6% |
| Other | 4% |
Research published from: USA.
How we got here
The name attaches to the pairing rather than to either molecule. BPC-157 comes out of the University of Zagreb, where Predrag Sikirić and colleagues characterised a fragment of a protein found in human gastric juice and published decades of rodent work on ulcer and tendon healing. TB-500 has a murkier commercial history. It is sold as a synthetic analogue related to thymosin beta-4, the actin-binding repair protein studied academically by Allan Goldstein and others and developed clinically for a time by RegeneRx under the name Tβ4. Vendors adopted the TB-500 designation for material that is often a shortened fragment rather than full-length thymosin beta-4, and the two names get used interchangeably in the grey market even though they are not always the same substance. The combination itself was assembled by users. It circulated through bodybuilding boards, Reddit peptide communities, MMA and jiu-jitsu circles, and podcast-adjacent biohacking media through the 2010s, where it picked up the Wolverine label after the Marvel character. No clinic, laboratory, or named individual is documented as having originated the stack or the nickname, and the pairing has never been formalised into a protocol by anyone with clinical authority.
BPC-157 was first isolated and characterized by researchers at the University of Zagreb in Croatia, who published most early animal work; it is derived from a protein sequence in human gastric juice. TB-500 is a synthetic peptide marketed as related to Thymosin Beta-4, a naturally occurring repair protein. The two were combined by the recovery and biohacking community rather than by formal clinical research. The 'Wolverine Stack' nickname is community/biohacker-attributed, referencing the X-Men character's regeneration; no individual creator is documented and the origin is uncertain. It is not a validated medical protocol.
Combined BPC-157 and TB-500 lineage and stack history
1981 to 2026
- 1981Thymosin β4 identified, with no BPC-157 milestoneThymosin β4 was isolated and sequenced as a 43-amino-acid peptide in bovine thymus, the earliest milestone in the TB-500 lineage, while no BPC-157 milestone was noted and the BPC line had not been described.
- 1989BPC parent line patented; TB-500 product identity not establishedYugoslav patent priority was assigned to the original gastric Body Protection Compound, the parent BPC line that later led to BPC-157, while no TB-500 milestone was noted and work remained focused on thymosin β4 biology rather than product identity.
- 1990sBPC-157 Animal StudiesUniversity of Zagreb researchers isolate and begin publishing on BPC-157 (animal studies).
- 1993BPC-157 documented as thymosin β4 research advancesBPC-157 appeared explicitly in patent and publication history with its 15-amino-acid sequence listed and early experimental papers, while no TB-500 product existed yet as thymosin β4 research advanced on cell migration and actin regulation.
- 1998Thymosin β4 wound-repair patent; no BPC-157 landmark notedThymosin β4 received patent priority in wound repair, helping establish the tissue-repair direction that later influenced the TB-500 story.
- 2000s-2010sWolverine is born around 2010TB-500 and BPC-157 circulate in research-chemical and bodybuilding markets.
- 2003BPC-157 tendon studies and TB-500 fragment researchRat Achilles tendon-healing studies helped establish BPC-157’s injury-repair reputation, while the 7-amino-acid fragment LKKTETQ was tested separately and became the main scientific ancestor of modern TB-500.
- 2012Preclinical BPC-157 literature and TB-500 fragment identificationBPC-157 already had substantial preclinical injury-repair literature, while a marketed TB-500 product was chemically identified as Ac-LKKTETQ, confirming that TB-500 is not full-length thymosin β4.
- 2023-2024FDA peptide regulationsFDA places BPC-157 in 503A compounding Category 2, citing safety and data concerns.
- July 2026PCAC reviewThe FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in July 2026 to recommend adding TB-500 and five other peptides to the 503A Bulks List, which would allow licensed compounding pharmacies to prepare them under specific conditions. no FDA approval
The people taking it
Orthopaedic sports medicine Gym Crowd Biohackers Ant-aging consumers
Orthopaedic sports medicine Gym Crowd Biohackers Ant-aging consumers
The sources describe use and regulatory attention mainly in the United States and the United Kingdom, with rules in sport that apply worldwide. In the United States, the FDA has not approved BPC-157 for human use. USADA and major leagues including the NFL, UFC and NCAA prohibit it, and the U.S. military prohibits BPC-157 in dietary supplements for service members. In the United Kingdom, a netnographic study of online forums documented self-reported use of BPC-157 and TB-500 for wellbeing and repair, with the peptides obtained through online platforms. Internationally, the World Anti-Doping Agency prohibits BPC-157 as a non-approved substance, and TB-500 and thymosin beta-4 as growth factors, at all times for athletes it governs. USADA states that BPC-157 is not approved for human clinical use by any global health authority. In equine sport, doping-control laboratories developed detection methods for TB-500 in horse urine and plasma because of reported misuse in racehorses.
What we do not know
- Is BPC-157 safe or effective for tendon, ligament, muscle or gut healing in people?
- Do the rodent healing results for BPC-157, which come mostly from one research group at the University of Zagreb, hold up when independent laboratories repeat them?
- Has combining BPC-157 with TB-500 ever been tested for safety or effect in a controlled study, in animals or in people?
- How are BPC-157 and TB-500 absorbed, spread, broken down and cleared in the human body?
- Is it safe to combine TB500 and BPC157 in the same vial? What about degradation?
- How will these peptides be regulated in the future? The FDA's classification of BPC-157 and related peptides for compounding has changed over time and was scheduled for further advisory committee review.
At a glance
- Amino acid sequence
- BPC-157 (GEPPPGKPADDAGLV) TB500 (Ac-LKKTETQ, residues 17 to 23)
- Amino acids
- Combined
- BPC-157 = Body Protection Compound 157
- 15-amino-acid peptide from gastric-juice protein
- TB-500
- synthetic fragment related to Thymosin Beta-4 protein
- Human RCTs
- 0
- FDA status
- not approved; restricted from compounding 2023-2024
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Wolverine Stack. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
TB-500 and thymosin beta-4 are explicitly named as prohibited growth factors, and BPC-157 falls under the prohibition on non-approved substances, at all times in and out of competition.
BPC-157 was placed in Category 2 of the bulk drug substances list for 503A compounding, reflecting significant safety risks and inadequate human data.
U.S. Food and Drug Administration
The FDA has warned that peptide products sold as research chemicals are not approved drugs and that unapproved injectable products carry contamination and dosing risks.
Most of the preclinical evidence for BPC-157 in tendon, ligament, muscle, and gastrointestinal healing comes from rodent studies published by the University of Zagreb group led by Predrag Sikirić.
Sikirić et al., peer-reviewed pharmacology literature indexed in PubMed
Thymosin beta-4 is an actin-sequestering protein with documented roles in cell migration, angiogenesis, and wound repair, characterised in the academic literature by Allan Goldstein and colleagues.
Full-length thymosin beta-4 was tested in registered human trials for dry eye, corneal wounds, and dermal ulcers, and did not reach marketing approval for any indication.
A search of registered trials returns no study evaluating BPC-157 and TB-500 administered together for injury recovery.
Anti-doping bodies have issued athlete advisories that peptides marketed for healing, including BPC-157 and TB-500, are prohibited and are a recurring source of sanctions.